SecBot SecBot
6-K ·Filed Sep 14, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
BULLISH
Impact 7/10
Horizonmonths Processed2mo ago SEC0001395064-26-000337
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor for FDA advisory committee briefing documents and potential label discussions ahead of the Q1 2027 PDUFA date. The strong Phase 3 data de-risks approval, but the binary regulatory event remains the key catalyst. Watch for any safety signals or manufacturing issues in the review process. The EMA review adds a second major regulatory catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$18.60
T+0 close · Sep 14, 2026 · via day close
Latest settled
+0.43%
T+20 · $18.68 · next T+60 in 21d
Vs SPY
−1.83%
α at T+20
Latest observation
+16.47%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $18.60entry
  2. T+1 · 2mo ago +0.54%α +1.00% · $18.70
  3. T+5 · 8w ago +1.56%α +1.45% · $18.89
  4. T+20 · 5w ago +0.43%α −1.83% · $18.68
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Takeda announced FDA Priority Review acceptance of its NDA for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, with a PDUFA target in Q1 2027. Phase 3 data showed strong efficacy across endpoints (e.g., ~70% sPGA 0/1 at week 16) with a clean safety profile, positioning it as a potential best-in-class oral TYK2 inhibitor. The EMA also accepted the MAA, and the filing has no impact on FY2027 guidance, making this a significant pipeline catalyst but with binary regulatory risk ahead.

Key Facts

  • FDA accepted NDA under Priority Review for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis.
  • PDUFA target action date is Q1 2027.
  • Phase 3 LATITUDE PsO 3001/3002 studies met all co-primary and 44 ranked secondary endpoints (p<0.001).
  • At week 16, 71% (3001) and 69% (3002) of zasocitinib patients achieved sPGA 0/1 vs 11%/13% placebo.
  • PASI 75 at week 16: 76% (3001) and 71% (3002) vs 12% placebo.
  • PASI 100 at week 16: 33% (3001) and 25% (3002) vs <1% placebo.
  • EMA also accepted the MAA for zasocitinib in plaque psoriasis.
  • No new safety signals; most common AEs were URTI (10.1%), nasopharyngitis (6.2%), and acne (6.5%).
  • NDA filing has no significant impact on FY2027 consolidated financial forecast.
  • Takeda is also evaluating zasocitinib in Phase 3 psoriatic arthritis and Phase 2 Crohn's, UC, vitiligo, and hidradenitis suppurativa.

Financial Impact

Pipeline catalyst with blockbuster potential; zasocitinib could address a large psoriasis market (66.4M patients globally). No immediate revenue impact as drug is not yet approved.

pipeline valuerevenue (future)

Risk Factors

  • Regulatory risk: FDA could issue a Complete Response Letter (CRL) or require additional data.
  • Commercial risk: Competition from existing oral (apremilast, deucravacitinib) and biologic therapies.
  • Execution risk: Manufacturing scale-up and launch execution for a potential blockbuster.
  • Pricing and reimbursement risk in a competitive psoriasis market.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000337
Document: 0001395064-26-000337-index-headers.html0001395064-26-000337
Document: 0001395064-26-000337-index.html0001395064-26-000337
Document: 0001395064-26-000337.txt0001395064-26-000337

Track record

18 reports on TAK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
  2. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  3. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  4. Oct 29, 202618d ago 6-K Neutral 4/10 No price data
  5. Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
  6. Sep 14, 20269w ago 6-K Bullish 7/10 Viewing Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
  7. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
  8. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
  9. Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 9h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026